Donald S. Fredrickson, M.D. 
- 2 - 
September 29, 1976 
should be broadly applicable and, consequently, view patent licenses as an 
unsuitable mechanism for their wide promulgation and enforcement. The ty- 
ing of patent licenses to commitments on Guidelines would create special 
responsibilities for licensees in an uneven way, a generally undesirable 
result, and possibly could deter potential developers from seeking licenses. 
Short of requiring commitment to the Guidelines by licensees, universities 
and government properly might call the attention of licensees to the Guide- 
lines and suggest compliance. 
In summary, we recommend that recombinant DNA patent matters be handled under 
current HEW policy and practices and suggest that guidelines can be implemented 
more fairly and effectively by means other than tying them to patent licenses. 
We hope the views expressed here will be helpful. If further exploration of 
them or of other aspects of the problem would be useful, we would be happy 
to discuss them with you. 
Sincerely yours, 
f 
D. I, Weisblat 
wm 
[ 118 ] 
